查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929555

球虫疫苗市场按产品类型、动物类型、给药途径、销售形式、最终用户、分销管道划分，全球预测（2026-2032年）

Coccidiosis Vaccines Market by Product Type, Animal Type, Administration Route, Sales Mode, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，球虫疫苗市场规模将达到 5.8084 亿美元，到 2026 年将成长至 6.3036 亿美元，到 2032 年将达到 9.1537 亿美元，复合年增长率为 6.71%。

主要市场统计数据
基准年 2025 5.8084亿美元
预计年份：2026年 6.3036亿美元
预测年份：2032年 9.1537亿美元
复合年增长率 (%) 6.71%

本文简要概述了目前影响家禽球球虫疫苗引入决策的科学进展、商业性压力和营运重点。

全球家禽业持续与球虫作斗争，这种顽固的感染疾病严重损害禽群健康、生产力和农场盈利。随着相关人员探索传统化疗的替代方案，疫苗已成为综合控制方案的核心，这些方案旨在平衡动物福利、生产效率以及抗菌药物使用方面的监管压力。本执行摘要总结了影响疫苗领域的科学、商业性和监管趋势，揭示了产品创新、给药方式和分销动态如何相互作用并影响疫苗的推广管道。

科学突破、营运需求和监管变化如何共同重塑家禽健康管理中疫苗研发的优先事项和交付管道

球虫疫苗产业正经历一场变革，这场变革是由科学、生产系统和监管等多面向因素共同推动的。分子生物学和免疫学的进步加速了重组疫苗和次单位疫苗候选产品的研发，使得筛选能够拓宽保护谱并降低反应原性的目标抗原成为可能。同时，载体疫苗平台和生产流程的改进降低了企业研发差异化产品的技术门槛，而精准给药策略则使疫苗更适合大规模商业化生产。

针对影响美国境内或与美国合作的疫苗相关人员所面临的关税变化，制定相应的战略应对措施，以促进供应链重组、本地化投资和商业合约的发展。

美国于2025年推出并调整的关税，为支持疫苗生产和分销的国际供应链带来了新的成本和战略复杂性。依赖跨境采购抗原、佐剂和专用反应器的製造商面临着采购不确定性的增加，这影响了库存计划和供应商多元化策略。值得注意的是，关税带来的成本压力往往会加速在地化进程，鼓励区域製造投资和供应伙伴关係关係，从而降低贸易波动带来的风险。

一个复杂的细分框架，将产品平台、管理路径、客户类型和分销管道与营运采纳和商业性成功联繫起来。

了解需求驱动因素和实施障碍需要明确区分产品类型、动物类型、给药途径、最终用户、分销管道和销售形式。以减毒活病毒疫苗、灭活疫苗、重组疫苗、次单位疫苗和载体疫苗类型对产品进行分类，会产生显着不同的商业性影响。减毒活病毒疫苗平台具有成熟的免疫抗原性特征和操作熟练度，但其特征在于存在早期株和野生型变异株，这些减毒活病毒疫苗在减毒程度、排放动力学和生产工艺要求方面各不相同。同时，重组疫苗和次单位疫苗候选产品优先考虑安全性和抗原特异性，通常需要先进的生产能力和低温运输供应。

区域监管重点、生产规模和分销能力如何共同决定全球家禽市场的商业性通路和市场接受趋势？

区域趋势正在显着影响美洲、欧洲、中东和非洲以及亚太地区的研发重点、製造地和市场推广策略。在美洲，监管机构对食品安全、动物福利以及大型加工企业间整合的重视，正在影响对可扩展疫苗解决方案和数据驱动型综合健康计划的需求。该地区还拥有强大的契约製造，商业农场与大型供应商合作以获得全面服务的趋势，正在加速采用管理效率更高的平台。

竞争定位和合作策略将决定哪些公司能够在禽类健康领域将科学差异化与持续应用和规模化相结合。

球虫疫苗领域的竞争反映了拥有成熟平台能力的现有企业与致力于研发新型抗原和递送技术的新兴参与企业之间的博弈。现有企业利用长期累积的田间数据、现有的分销网络和技术支援团队，并与大型商业生产商和一体化营业单位保持良好的合作关係。他们通常专注于在菌株选择、生产效率和剂量相容性方面进行渐进式改进，以维护现有基本客群并确保供应的连续性。

企业应优先采取切实有效、影响深远的策略措施，以加速技术采纳、减少商业性摩擦并建立具有韧性的供应链和分销模式。

为了在不断变化的环境中实现永续价值，产业领导者必须务实地结合产品创新、协作和商业性灵活性。投资于能够降低反应原性并维持广谱保护的平台技术，将有助于製造商同时满足动物福利期望和生产需求。同时，优先考虑能够融入孵化场和养殖场工作流程的给药途径（例如卵内、水源性等），将减少营运摩擦，而这些摩擦往往会阻碍大规模应用。

我们采用透明、依证的研究途径，结合关键相关人员的意见、技术检验和供应链分析，从而产生可执行的商业性洞察。

本分析采用透明、可重复的调查方法，结合一手与二手研究，兼顾技术严谨性和实际应用价值。一级资讯来源包括对商业领袖、兽医和生产经理的结构化访谈，以及与免疫学家和生产专家的技术咨询，以检验菌株特征、给药可行性和操作限制。二级资讯来源包括同侪审查文献、监管指导文件和公开文件，以支援该平台的功能、安全性和核准流程。

一项综合分析重点阐述如何整合策略，将技术进步转化为永续的疾病控制和商业性价值。

分析结果展现了一幅务实创新的整体情况。科学进步正在拓展球虫防治手段，但商业性成功取决于能否将这些进步与现代家禽生产的实际情况以及不断发展的贸易和法律规范相契合。将生物分化技术与可控的交付模式和完善的售后支援相结合的研发者最有可能实现持续推广。同时，关税波动和区域监管差异也提升了供应链韧性和社区伙伴关係的策略价值。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章球虫疫苗市场（依产品类型划分）

  • 减毒活病毒疫苗
    • 早熟型
    • 野生型
  • 灭活疫苗
  • 重组疫苗
  • 次单位疫苗
  • 载体疫苗

第九章 依动物类型球虫疫苗市场

  • 肉鸡
  • 产蛋鸡
  • 火鸡

第十章球虫疫苗市场依给药途径划分

  • 注射
  • 口服
    • 饲料添加剂型
    • 卵内给药
    • 饮用水管理

第十一章 依销售类型球虫疫苗市场

  • 非处方药
  • 处方药

第十二章球虫疫苗市场（依最终用户划分）

  • 商业家禽养殖场
  • 综合家禽生产商
  • 研究所

第十三章球虫疫苗市场（依通路划分）

  • 直销
  • 经销商
  • 线上管道

第十四章球虫疫苗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章球虫疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国球球虫疫苗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国球虫疫苗市场

17. 中国球虫疫苗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Animalcare Group plc
  • APHA
  • BIMeda, Inc.
  • Bioproperties（Hubei）BIoTechnology Co., Ltd.
  • Ceva Sante Animale SA
  • CEVAC
  • Elanco Animal Health Incorporated
  • Elanco Operations LLC
  • Hester Biosciences Limited
  • Huvepharma AD
  • IDT Biologika GmbH
  • ImmuCell Corporation
  • Indian Immunologicals Limited
  • Intervet International BV
  • Laboratorios Hipra, SA
  • Lohmann Animal Health International GmbH
  • Merck Sharp & Dohme Corp.
  • MSD Animal Health UK Limited
  • Pharmaq AS
  • Phibro Animal Health Corporation
  • The Chemo-Sero-Therapeutic Research Institute（Kaketsuken）
  • Vaxxinova International BV
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-0A3806951816

The Coccidiosis Vaccines Market was valued at USD 580.84 million in 2025 and is projected to grow to USD 630.36 million in 2026, with a CAGR of 6.71%, reaching USD 915.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 580.84 million
Estimated Year [2026] USD 630.36 million
Forecast Year [2032] USD 915.37 million
CAGR (%) 6.71%

A concise orienting overview that frames current scientific advances, commercial pressures, and operational priorities shaping coccidiosis vaccine decision-making in poultry

The global poultry sector continues to contend with coccidiosis as one of the most persistent infectious diseases undermining flock health, productivity, and farm-level profitability. As stakeholders pursue alternatives to traditional chemotherapeutics, vaccines have become central to integrated control programs that balance animal welfare, production efficiency, and regulatory pressures around antimicrobial use. This executive summary synthesizes scientific, commercial, and regulatory developments shaping the vaccine landscape, highlighting how product innovation, administration practices, and distribution dynamics intersect to influence adoption pathways.

This report places particular emphasis on product differentiation across attenuated live and next-generation platforms, shifts in administration practices such as in-ovo and in-water delivery, and the evolving roles of commercial poultry producers and integrated enterprises in procurement and deployment. It integrates cross-cutting themes including biosecurity, supply chain resilience, and the influence of trade policy on manufacturing and sourcing decisions. Ultimately, the introduction frames the critical choices facing research and commercial leaders seeking to translate efficacy data into scalable, cost-effective interventions that reduce disease burden while meeting consumer and regulatory expectations.

How scientific breakthroughs, operational demands, and regulatory shifts are jointly redefining vaccine development priorities and adoption pathways in poultry health

The coccidiosis vaccine landscape is in the midst of transformative shifts driven by converging forces in science, production systems, and regulation. Advances in molecular biology and immunology have accelerated the development of recombinant and subunit vaccine candidates, enabling targeted antigen selection that can reduce reactogenicity while broadening protective profiles. Concurrently, improvements in vector vaccine platforms and manufacturing processes have lowered technical barriers for companies seeking differentiated offerings, and precision delivery approaches are making vaccines more compatible with large-scale commercial operations.

At the production level, integrated poultry producers and large commercial farms are exerting greater influence over procurement decisions, favoring products that demonstrate operational compatibility with mass administration methods and that align with welfare and sustainability commitments. Administration routes such as in-ovo and in-water delivery are gaining traction because they reduce handling time and labor intensity while supporting more uniform immunization across cohorts. Regulatory landscapes have also tightened around antimicrobial stewardship, indirectly amplifying the commercial imperative to adopt effective vaccination regimens. Taken together, these shifts are raising the bar for product developers to demonstrate not only biological efficacy but also delivery practicality, manufacturability, and traceable safety profiles that meet buyers' operational realities.

Strategic responses to tariff changes that are reshaping supply chains, localization investments, and commercial agreements for vaccine stakeholders operating in and with the United States

The introduction and adjustment of U.S. tariffs in 2025 have introduced new layers of cost and strategic complexity for international supply chains that underpin vaccine production and distribution. Manufacturers that rely on cross-border inputs for antigen production, adjuvants, or specialized bioreactors face increased procurement uncertainty, which, in turn, influences inventory planning and supplier diversification strategies. Importantly, tariff-induced cost pressure tends to accelerate localization efforts by incentivizing regional manufacturing investments and supply partnerships that reduce exposure to trade volatility.

For exporters and multinational firms serving the U.S. market, tariff changes have encouraged re-evaluation of pricing strategies, contractual terms with distributors, and the structure of commercial agreements to absorb or pass through increased landed costs. Meanwhile, distributors and direct sales channels are adapting by seeking value-added services-such as bundled logistics or inventory financing-to mitigate margin compression. On the policy side, heightened tariff environments have amplified the importance of demonstrating domestic value creation through local production, joint ventures, and technology transfer initiatives. Consequently, strategic responses to tariff shifts are not limited to short-term cost management but extend to long-term portfolio localization, route-to-market redesign, and strengthened ties with domestic stakeholders to preserve market access and competitiveness.

A nuanced segmentation framework linking product platforms, administration pathways, customer types, and sales channels to operational adoption and commercial success

Understanding demand drivers and adoption barriers requires clear segmentation across product type, animal type, administration route, end user, distribution channel, and sales mode. When products are categorized by type-Attenuated Live Vaccine, Inactivated Vaccine, Recombinant Vaccine, Subunit Vaccine, and Vector Vaccine-the commercial implications vary markedly: attenuated live platforms bring established immunogenicity profiles and operational familiarity, with attenuated live options further characterized by Precocious strains and Wild Type variants that differ in attenuation, shedding dynamics, and production handling requirements. In contrast, recombinant and subunit candidates prioritize safety and antigen specificity, often demanding advanced manufacturing capabilities and cold chain assurances.

Animal-type segmentation-broiler chickens, layer chickens, and turkeys-drives distinct dosing strategies, timing considerations, and economic thresholds for vaccine interventions because production cycles and value-per-bird differ across these groups. Administration-route segmentation offers operational trade-offs: injection-based approaches deliver precise dosing but increase labor and stress on birds, while oral delivery methods such as in-feed, in-ovo, and in-water administration facilitate mass immunization and align with automated production workflows, although they require formulation stability and robust delivery protocols. End-user distinctions among commercial poultry farms, integrated poultry producers, and research institutes influence procurement sophistication and adoption timelines; large integrated producers often demand scalable administration solutions and data integration, whereas research institutes prioritize novel platforms and experimental flexibility. Distribution-channel segmentation across direct sales, distributors, and online channels affects lead times, after-sales support, and cold chain integrity, with direct sales enabling closer technical collaboration and online channels offering efficiency for standardized products. Finally, sales-mode segmentation into Over-The-Counter and Prescription pathways shapes regulatory compliance, veterinary oversight, and purchaser responsibility for on-farm use. Taken together, these intersecting segmentation lenses create a complex decision matrix for developers and purchasers, requiring tailored value propositions that match product attributes to operational realities and regulatory obligations.

How regional regulatory priorities, production scales, and distribution capabilities converge to determine commercial pathways and adoption dynamics across global poultry markets

Regional dynamics materially shape research priorities, manufacturing footprints, and route-to-market strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory emphasis on food safety, animal welfare, and consolidation among large processors influences demand for scalable vaccine solutions and integrated data-driven health programs. This region also exhibits robust contract manufacturing capacity and a propensity for commercial farms to partner with large suppliers for bundled services, which accelerates diffusion of administratively efficient platforms.

In Europe, Middle East & Africa, regulatory stringency and consumer expectations around antibiotic stewardship create a favorable environment for vaccines that demonstrate clear welfare and residue advantages, while diverse farming systems in the EMEA region necessitate flexible delivery options that can be adapted to smallholder as well as commercial contexts. The Asia-Pacific region remains a focal point for both production volume and innovation, driven by large poultry populations, variable regulatory regimes, and growing investment in regional manufacturing. In this region, in-ovo and in-water administration solutions are particularly attractive because they scale with high-throughput hatchery and grow-out operations. Across these geographies, manufacturers must tailor registration approaches, distribution models, and technical support to local regulatory frameworks and producer practices, recognizing that success hinges on combining scientific differentiation with logistical suitability and culturally informed commercial engagement.

Competitive positioning and collaboration strategies that determine which companies translate scientific differentiation into sustained adoption and operational scale in poultry health

Competitive dynamics in the coccidiosis vaccine space reflect an interplay between legacy players with established platform capabilities and newer entrants pursuing novel antigen and delivery technologies. Established manufacturers leverage longitudinal field data, existing distribution networks, and technical support teams to maintain trust among large commercial producers and integrated operations. They often focus on incremental improvements in strain selection, manufacturing efficiency, and administration compatibility to protect installed bases and demonstrate continuity of supply.

Emerging companies and specialized biotech firms concentrate on recombinant, subunit, and vector-based platforms, emphasizing differentiated safety profiles, targeted immune responses, and potential compatibility with precision delivery methods. These companies frequently form strategic alliances with contract manufacturers, hatcheries, and distributor partners to accelerate field trials and scale-up. Across the competitive landscape, collaboration between vaccine developers, integrators, and feed or hatchery operators is becoming a competitive advantage because it shortens adoption cycles and addresses operational barriers to implementation. Intellectual property around antigen constructs and delivery technologies, combined with proven field performance and robust post-market surveillance, will determine which firms secure long-term commercial traction in diverse production environments.

Practical, high-impact strategic moves that companies should prioritize to accelerate adoption, reduce commercial friction, and build resilient supply and distribution models

Industry leaders must adopt a pragmatic mix of product innovation, operational alignment, and commercial agility to capture sustainable value in this evolving environment. Investment in platform technologies that reduce reactogenicity while maintaining broad protective coverage will help manufacturers meet both welfare expectations and production imperatives. Concurrently, prioritizing administration routes that integrate with hatchery and farm workflows-such as in-ovo and in-water options-will lower the operational friction that often impedes adoption at scale.

Strategically, firms should pursue supply-base diversification and regional manufacturing collaborations to mitigate trade-related cost volatility and to meet local regulatory requirements more efficiently. Commercial teams need to design value propositions that extend beyond product performance to include training, cold chain assurance, and post-deployment surveillance services that reduce perceived buyer risk. Finally, forging partnerships with integrators, feed companies, and hatcheries can create bundled solutions that shorten the sales cycle and embed vaccines into standard operating procedures, thereby converting clinical benefits into measurable operational outcomes. Executing on these priorities requires cross-functional alignment between R&D, regulatory, manufacturing, and commercial teams, supported by targeted investments in field validation and customer education.

A transparent, evidence-based research approach blending primary stakeholder input, technical validation, and supply chain mapping to generate actionable commercial intelligence

This analysis synthesizes primary and secondary research under a transparent, reproducible methodology that balances technical rigor with practical relevance. Primary inputs included structured interviews with commercial leaders, veterinarians, and production managers, complemented by technical consultations with immunologists and manufacturing specialists to verify strain characteristics, delivery feasibility, and operational constraints. Secondary inputs encompassed peer-reviewed literature, regulatory guidance documents, and public filings that were used to corroborate platform capabilities, safety profiles, and approval pathways.

Qualitative synthesis emphasized triangulation across sources to identify consistent themes and potential inflection points, while methodological safeguards included cross-validation of interview findings against published evidence and regulatory frameworks. The research team also evaluated route-to-market considerations through supply chain mapping and stakeholder role analysis to ensure recommendations align with real-world procurement and distribution practices. Limitations of the methodology are acknowledged where direct head-to-head field data were not available, and in such instances the analysis highlights evidence gaps and proposes targeted study designs for future validation. The overall approach prioritizes actionable insight generation while maintaining methodological transparency and traceability of analytic judgments.

A synthesis highlighting how integrated scientific, operational, and policy strategies convert technological advances into sustained disease control and commercial value

The cumulative picture emerging from this analysis is one of pragmatic innovation: scientific advances are expanding the toolbox for coccidiosis control, but commercial success depends on aligning those advances with the operational realities of modern poultry production and the shifting contours of trade and regulation. Developers that couple biological differentiation with administratively efficient delivery formats and robust post-market support are most likely to achieve durable adoption. At the same time, tariff dynamics and regional regulatory variability increase the strategic premium on supply chain resilience and localized partnerships.

For decision-makers, the path forward involves prioritizing investments that reduce adoption friction-whether through formulation stability for oral delivery, service models that simplify on-farm implementation, or localized manufacturing that mitigates trade exposure. By integrating scientific rigor with commercial pragmatism and proactive stakeholder engagement, companies can convert technical promise into field impact while supporting broader industry goals around animal health, welfare, and responsible antibiotic use. The conclusion emphasizes that durable progress will arise from coordinated action across R&D, manufacturing, policy engagement, and frontline commercial support.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coccidiosis Vaccines Market, by Product Type

  • 8.1. Attenuated Live Vaccine
    • 8.1.1. Precocious
    • 8.1.2. Wild Type
  • 8.2. Inactivated Vaccine
  • 8.3. Recombinant Vaccine
  • 8.4. Subunit Vaccine
  • 8.5. Vector Vaccine

9. Coccidiosis Vaccines Market, by Animal Type

  • 9.1. Broiler Chickens
  • 9.2. Layer Chickens
  • 9.3. Turkeys

10. Coccidiosis Vaccines Market, by Administration Route

  • 10.1. Injection
  • 10.2. Oral
    • 10.2.1. In-Feed
    • 10.2.2. In-Ovo
    • 10.2.3. In-Water

11. Coccidiosis Vaccines Market, by Sales Mode

  • 11.1. Over-The-Counter
  • 11.2. Prescription

12. Coccidiosis Vaccines Market, by End User

  • 12.1. Commercial Poultry Farms
  • 12.2. Integrated Poultry Producers
  • 12.3. Research Institutes

13. Coccidiosis Vaccines Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Channels

14. Coccidiosis Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Coccidiosis Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Coccidiosis Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Coccidiosis Vaccines Market

18. China Coccidiosis Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Animalcare Group plc
  • 19.6. APHA
  • 19.7. BIMeda, Inc.
  • 19.8. Bioproperties (Hubei) Biotechnology Co., Ltd.
  • 19.9. Ceva Sante Animale S.A.
  • 19.10. CEVAC
  • 19.11. Elanco Animal Health Incorporated
  • 19.12. Elanco Operations LLC
  • 19.13. Hester Biosciences Limited
  • 19.14. Huvepharma AD
  • 19.15. IDT Biologika GmbH
  • 19.16. ImmuCell Corporation
  • 19.17. Indian Immunologicals Limited
  • 19.18. Intervet International B.V.
  • 19.19. Laboratorios Hipra, S.A.
  • 19.20. Lohmann Animal Health International GmbH
  • 19.21. Merck Sharp & Dohme Corp.
  • 19.22. MSD Animal Health UK Limited
  • 19.23. Pharmaq AS
  • 19.24. Phibro Animal Health Corporation
  • 19.25. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
  • 19.26. Vaxxinova International BV
  • 19.27. Vetoquinol S.A.
  • 19.28. Virbac S.A.
  • 19.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COCCIDIOSIS VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COCCIDIOSIS VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRECOCIOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRECOCIOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRECOCIOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY WILD TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY WILD TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY VECTOR VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY VECTOR VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY VECTOR VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY BROILER CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY BROILER CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY BROILER CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY LAYER CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY LAYER CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY LAYER CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY TURKEYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY TURKEYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY TURKEYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-OVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-OVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-OVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INTEGRATED POULTRY PRODUCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INTEGRATED POULTRY PRODUCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INTEGRATED POULTRY PRODUCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)